{"doi":"10.2174/138161206776055822","title":"Advances in HIV-1 Entry Inhibitors: Strategies to Interfere with Receptor and CoReceptor Engagement","abstract":null,"journal":"Current Pharmaceutical Design","year":2006,"id":19197,"datarank":1.3250188974667536,"base_score":2.8903717578961645,"endowment":2.8903717578961645,"self_citation_contribution":0.4335557636844247,"citation_network_contribution":0.8914631337823289,"self_endowment_contribution":0.4335557636844247,"citer_contribution":0.8914631337823289,"corpus_percentile":null,"corpus_rank":null,"citation_count":17,"citer_count":17,"citers_with_citation_signal":15,"citers_with_endowment":15,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":130885,"name":"Ingrid Markovic","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"base_score":2.8903717578961645,"endowment":2.8903717578961645,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"16515489","pmcid":null,"openalex_id":"https://openalex.org/W2019665678","authors":[],"funders":[],"total_grants":0,"fwci":1.72837489,"citation_percentile":0.81546527,"influential_citations":2,"citation_trend":[{"year":2013,"count":1}],"oa_status":"closed","license":null,"oa_locations":[{"url":"http://eurekaselect.com/article/download/56008","host_type":"publisher"},{"url":"https://doi.org/10.2174/138161206776055822","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/16515489","host_type":"repository"}],"fields_of_study":["HIV/AIDS drug development and treatment","Click Chemistry and Applications","Chemical Synthesis and Analysis","Biology","Medicine","Animals","HIV Fusion Inhibitors","HIV Infections","HIV-1","Humans","Models, Biological","Receptors, HIV"],"mesh_terms":["Animals","HIV Fusion Inhibitors","HIV Infections","HIV-1","Humans","Models, Biological","Receptors, HIV"],"keywords":["Enfuvirtide","Viral entry","Maraviroc","Viral envelope","Gp41","CCR5 receptor antagonist","Lipid bilayer fusion","Chemokine receptor","Entry inhibitor","Viral life cycle","Virology","Biology","Viral replication","Receptor","Human immunodeficiency virus (HIV)","Chemokine","Virus","Immunology","Antibody","Biochemistry"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Responsible consumption and production"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-06-04T02:33:26.354812Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}